Ipsen pays €12m tasquinimod milestone for prostate cancer trial
This article was originally published in Scrip
Active Biotech of Sweden has received a milestone payment of from Ipsen for an "undisclosed clinical event" related to the 10TASQ10 study in metastatic castration-resistant prostate cancer (mCRPC) patients for tasquinimod, CEO Tomas Leanderson told Scrip.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.